Oisin Biotechnologies

Oisín Biotechnologies is a company dedicated to developing genetic medicines focused on health and longevity. They are working on a pipeline of therapies that target the underlying causes of age-related conditions. Their approach involves stimulating muscle growth, selectively eliminating fat cells, and removing senescent cells, all aimed at tackling the challenges of frailty.

Oisín leverages their proprietary Fusogenix™ Proteo-Lipid Vehicle (PLV) technology for drug delivery. This non-viral method allows for extensive distribution beyond the liver, accommodating both DNA and RNA payloads, and enabling safe repeated dosing. The company is headquartered in Seattle, Washington, and boasts a strong team of executives and board members with expertise in the field.

Oisín Biotechnologies is dedicated to developing innovative genetic medicines that target the root causes of age-related conditions. They focus on stimulating muscle growth, selectively killing fat cells, and removing senescent cells to combat frailty and promote longevity. Their therapies utilize a proprietary non-viral delivery technology called Fusogenix™ Proteo-Lipid Vehicle (PLV), which enables extensive extrahepatic biodistribution for both DNA and RNA payloads, allowing for safe and repeated dosing.